Participant Information Sheets
There are three phases within TebeMRD trial. For the pre-screening phase, we aim to recruit approximately 850 participants overall, from up to 50 hospitals across the UK. Of these 850 patients, we estimate that approximately 350-380 patients will be eligible to proceed to the molecular screening phase of the trial. If molecular signs of relapse are identified during the year of screening, participants will be invited to be treated with tebentafusp. For the main treatment phase, we aim to recruit up to 50 evaluable patients to receive Tebentafusp treatment.
Please use the links below to access the Patient Information Sheets for a detailed explanation of each phase of the trial:
